All Nippon Airways will cooperate with Joby, an enterprise invested by Toyota, on the flying car business, which is planned to be practical in 2025

Clinical CRO Tigermed: The ‘Small and Beautiful’

In this race of pharmaceutical R&D outsourcing segment, WuXi AppTec, Pharmaron, Tigermed and Asychem are some of the major names – but which has a truly winning side?

Thinking of ASEAN as a single market is the biggest miscalculation for Chinese companies

For a long time, multinational corporations have often held a dangerous "holistic" bias when examining the Association of Southeast Asian Nations (ASEAN). This perspective views ASEAN—a region with over 690 million people and interwoven diverse cultures—as a single emerging market, attempting to capture one country as a model and then replicating that pattern across other member states.

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

CRO Giant Tigermed’s 1H 2020 Net Profits Up 98%

Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.

WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell

According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index.  It has been considered a top holding by many MSCI China indexes for some time.